The SSRI discontinuation syndrome.
A characteristic selective serotonin reuptake inhibitor (SSRI) discontinuation syndrome appears to exist. It is usually mild, commences within 1 week of stopping treatment, resolves spontaneously within 3 weeks, and consists of diverse physical and psychological symptoms, the commonest being dizziness, nausea, lethargy and headache. SSRI reinstatement leads to resolution within 48 h. A transient stage of serotonin dysregulation appears central to causation with pharmacokinetic and pharmacodynamic differences accounting for the variation in incidence between the SSRIs. Discontinuation reactions are clinically relevant due to the associated morbidity, the potential for misdiagnosis and inappropriate treatment and because they may impair future antidepressant compliance. To minimize incidence, SSRIs, like other antidepressants, should be withdrawn gradually. Provisional diagnostic criteria for the SSRI discontinuation syndrome are proposed. Prospective studies are required to investigate the syndrome, particularly its effects on patient care.
Haddad
P
P
Moorside, Trafford General Hospital, Davyhulme, Manchester, UK.
D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy
D017367:Selective Serotonin Reuptake Inhibitors